2023-06-13-艾昆纬-监测新冠肺炎对欧盟4国和英国医药市场的影响_67页_1mb

确保让用户可以独立阅读，重点关注关键发现和影响，而不是冗长的具体数据。

Long COVID Overview

• Definition: Post-acute sequelae of SARS-CoV-2 infection (PASC)，指新冠病毒感染后3个月内出现的、持续2个月以上且不能用其他诊断解释的症状。
• Common Symptoms: 疲劳、注意力不集中、肌肉疼痛、呼吸困难等。
• Prevalence (UK): 约2.9%的英国人口受Long COVID影响，其中150万人日常活动受到严重影响。
• Vulnerable Groups: 年龄介于35-69岁之间、女性、生活在贫困地区的居民等。
• Treatment Challenges: Long COVID尚未被所有国家医疗卫生系统普遍承认为一种医学疾病，疗法基于对症状的管理而非针对性治疗，保险公司常将Long COVID排除在慢性病覆盖范围之外。
• Economic Impact (OECD): 年级生命年损失估计高达7.0-142.0亿欧元，经济损失累计达723-3170亿欧元。
• Research Focus: 旨在更好地理解其发病机制、进行早期诊断、开发治疗方法、制定指南、提供康复支持，并通过国际合作开展相关研究。

COVID-19 Variants and Vaccination

• Vaccination: EU4+UK have administered ~748 million doses, over 200 million dose across all individuals per 100 people, ~85%+ population fully vaccinated.
• Vaccine Types: Pfizer/BioNTech is the most widely used primary/vaccine product globally, followed by Moderna (in some regions), with bivalent boosters (e.g., J&J Paxlovid candidates being evaluated) being integrated.
• Boosters: widely rolled out, e.g., UK targeting seniors/care home residents/immunosuppressed, >50% adults in EU vaccinated. Booster rates high across Europe, with Belgium leading per 100 people.
• Variants: Globally tracked by WHO/ECDC; Omicron still dominant; Diverse variants spreading, some resistant to existing vaccines (BQ-1, BQ.1.1).

Medicine Demand and Supply

• Retail Growth: Germany/UK: +6.5%/+5.5% YTD2023 vs YTD2022; Italy/Spain: +5.5%/+5.7%.
• Hospital Growth: Germany/UK: +5.9%/+8.4% YTD2023 vs YTD2022; France/Spain: +6.1%/+9.0%.
• Key Drivers: Growth driven by antiparasitic, respiratory, analgesics, corticosteroid, antineoplastic products, and vaccines.
• Consumer Health: France shows slight negative YTD growth (-0.7% overall, -1.1% CH category growth), while others like UK show positive. Consumption shifted towards respiratory/OTC initially during COVID peak.

Engagement with Health Care Professionals

• Promotional Shift: Decrease in F2F interactions (-29% to -41%), increase in remote interaction (primarily phone/e-detailing +3% to +24%). Hybrid model prevalent (approx. 85-95% F2F interaction combined F2F/Remote).
• Channel Trends: High conversion rates (>84%) observed in IQVIA Channel Dynamics data for both F2F and remote interactions. Digital tools (e-detailing, e-meetings) increasingly utilized.

Research and Market Impact

• EU4/UK Contribution: Account for 14% of total drugs underdevelopment for COVID-19, heavily concentrated in injectables & oral medications.
• Recent News: EU/EMAauthorize booster for children; Changing/increasing use of bivalent boosters; US expands bivalent authorization to younger agegroups.

Key Takeaways Summary

• Long COVID: Significant health challenge with substantial economic loss, impacting work and diminishing quality of life.
• Vaccination & Boosters: Near-universal coverage in EU4/UK with strong booster uptake, focusing on protecting vulnerable populations.
• Market Trends: Despite overall system stabilization post-COVID, retail sales remain dynamic (particularly in non-pharma channels) and hospital/primary care units continue to see growth in specific therapeutic areas like respiratory, antineoplastics, corticosteroids. Supply chain challenges easing.
• Disease Burden: Long-Term complications significantly impact daily life and economics, demanding focused R&D and clinical management solutions.